

UNITED THERAPEUTICS CORP  
Form 8-K  
May 01, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15 (d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 1, 2008**

**United Therapeutics Corporation**

(Exact Name of Registrant as Specified in Charter)

|                                                                                                   |   |                                 |   |                                       |
|---------------------------------------------------------------------------------------------------|---|---------------------------------|---|---------------------------------------|
| <b>Delaware</b><br>(State or Other                                                                | - | <b>000-26301</b><br>(Commission | - | <b>52-1984749</b><br>(I.R.S. Employer |
| Jurisdiction of                                                                                   |   | File Number)                    |   | Identification Number)                |
| Incorporation)                                                                                    | - |                                 | - |                                       |
| <b>1110 Spring Street</b><br><b>Silver Spring, MD</b><br>(Address of Principal Executive Offices) |   |                                 |   | <b>20910</b><br>(Zip Code)            |

Edgar Filing: UNITED THERAPEUTICS CORP - Form 8-K

Registrant's telephone number, including area code:

**(301) 608-9292**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On May 1, 2008, United Therapeutics Corporation issued a press release discussing the results of its Annual Meeting and the adjournment of its Annual Meeting to be reconvened on May 29, 2008, to consider the approval of the Amended and Restated 2008 United Therapeutics Corporation Equity Incentive Plan.

A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Exhibits**

This information shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

d) Exhibits

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>   |
|--------------------|---------------------------------|
| 99.1               | Press release dated May 1, 2008 |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: May 1, 2008

By:

/s/ Paul A. Mahon

Name:

Paul A. Mahon

Title:

General Counsel

---

**Exhibit Index**

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>   |
|--------------------|---------------------------------|
| 99.1               | Press release dated May 1, 2008 |

---